This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 2 of 3 for:    corcept pittsburgh

Study to Evaluate CORT125134 in Patients With Cushing's Syndrome

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2017 by Corcept Therapeutics
Information provided by (Responsible Party):
Corcept Therapeutics Identifier:
First received: June 15, 2016
Last updated: June 15, 2017
Last verified: June 2017

Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol. Endogenous Cushing's syndrome resulting from cortisol overproduction by the adrenal glands is the subject of this protocol.

Patients with exogenous Cushing's syndrome, which develops as a side effect of chronic administration of high doses of glucocorticoids, are not eligible for enrollment in this study.

The purpose of this study is to evaluate the safety and efficacy of CORT125134 for treatment of endogenous Cushing's syndrome. The multicenter study will be conducted in the United States and in Europe.

Condition Intervention Phase
Cushing's Syndrome Drug: CORT125134 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing's Syndrome

Resource links provided by NLM:

Further study details as provided by Corcept Therapeutics:

Primary Outcome Measures:
  • General safety of CORT125134 in patients with endogenous Cushing's syndrome. [ Time Frame: 12 months ]
    The safety profile of CORT125134 in patients with Cushing's syndrome as assessed by physical examination findings, vital signs, ECG results, clinical laboratory tests, adverse events (CTCAE v4.0) and concomitant medications.

Secondary Outcome Measures:
  • The evidence of reduction in cortisol activity following treatment of CORT125134 in patients with endogenous Cushing's syndrome. [ Time Frame: 12 months ]
    The reduction in cortisol activity following treatment with CORT125134 in patients with endogenous Cushing's syndrome based on improvement in glucose control and/or blood pressure.

Estimated Enrollment: 30
Study Start Date: June 2016
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CORT125134

Group 1: 100 mg/day for 4 weeks, then 150 mg/day for 4 weeks, then 200 mg/day for 4 weeks.

Group 2: 250 mg/day for 4 weeks, then 300 mg/day for 4 weeks, then 350 mg/day for 4 weeks.

Drug: CORT125134

Detailed Description:

This is a Phase 2, open-label study with two dose groups, each with a two-step dose escalation, designed to evaluate the safety and efficacy of CORT125134 for the treatment of endogenous Cushing's syndrome. CORT125134 will be administered orally once daily for 12 weeks with dose escalations occuring every 4 weeks.

PK profiles will be generated at every dose level. A data review committee will review PK and safety data and will recommend the final plan for dose escalation in Group 2.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Has a confirmed diagnosis of endogenous Cushing's syndrome.
  2. Requires medical treatment of hypercortisolemia.
  3. Meets at least one of the following criteria:

    1. Has type 2 diabetes mellitus.
    2. Has impaired glucose tolerance.
    3. Has hypertension.

Exclusion Criteria:

  1. Has non-endogenous source of hypercortisolemia
  2. Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism
  3. Has poorly controlled hypertension
  4. Has Stage ≥ 4 renal failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02804750

Contact: Clinical Study Lead

United States, Colorado
Aurora, Colorado, United States, 80045
United States, Florida
Fort Lauderdale, Florida, United States, 33312
Miami, Florida, United States, 33136
United States, Indiana
Indianapolis, Indiana, United States, 46202
United States, Minnesota
Rochester, Minnesota, United States, 55905
United States, Pennsylvania
Pittsburgh, Pennsylvania, United States, 15212
United States, Virginia
Richmond, Virginia, United States, 23119
United States, Washington
Seattle, Washington, United States, 98122
Budapest, Hungary
Pecs, Hungary
Cuneo, Italy
Messina, Italy
Milano, Italy
Naples, Italy
Orbassano, Italy
Roma, Italy
Siena, Italy
Torino, Italy
Leiden, Netherlands
Rotterdam, Netherlands
United Kingdom
Salford, Manchester, United Kingdom
Sponsors and Collaborators
Corcept Therapeutics
Study Director: Andreas G Moraitis, MD Corcept Therapeutics
  More Information

Responsible Party: Corcept Therapeutics Identifier: NCT02804750     History of Changes
Other Study ID Numbers: CORT125134-451
Study First Received: June 15, 2016
Last Updated: June 15, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Corcept Therapeutics:
Cushing's Syndrome
Cushing's Disease
Type 2 Diabetes
Impaired Glucose Intolerance
Adrenal Corticotrophic Hormone (ACTH)
Adrenocortical Carcinoma
Primary Pigmented Nodular Adrenal Disease (PPNAD)
Moon Facies
Dorsocervical Fat Pad
Adrenal Adenoma
Adrenal Carcinoma
Adrenal Autonomy

Additional relevant MeSH terms:
Cushing Syndrome
Pathologic Processes
Adrenocortical Hyperfunction
Adrenal Gland Diseases
Endocrine System Diseases processed this record on September 21, 2017